Journey of an mAb through IND and BLA filing

March 23, 2022

Your monoclonal antibody candidates need extensive stability characterization along their journey to become commercial drugs. This is done to ensure the quality and safety of the final drug for both clinical trials and marketing approval by the FDA. 

This infographic outlines a typical timeline to launch a new mAb-based drug. It focuses on the role of stability studies during the filing of the Investigational New Drug (IND) application – to authorize clinical investigations, and also the Biologics License Application (BLA) – the request for FDA authorization to market a mAb therapeutic.

Learn about the definitions and objectives of both IND and BLA processes, and the importance of stability studies throughout the different phases of approval.

Timeline infographic on IND and BLA processes and role of stability studies during the FDA filing process

Previous Video
DLS easily explained: What it tells you about your protein
DLS easily explained: What it tells you about your protein

Join this webinar to learn about the physical phenomenon that drives Dynamic Light Scattering (DLS), and se...

Up next
Overcome bottlenecks in viral vector manufacturing
Overcome bottlenecks in viral vector manufacturing

The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer t...

Ready to tackle your challenging stability characterizations?

Discover tools